We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’ Substack by Kontra. In this ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD).

Sanofi has acquired rights to co-develop and co-market Teva’s TEV-48574, currently in phase 2b testing for both ulcerative colitis and Crohn’s disease, with results expected next year.

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

The global allergic rhinitis market is poised for substantial growth from 2025 to 2035, driven by a rise in allergic diseases, and advancements in th ...

JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine ...

BURLINGAME, CA, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Fast Melt Tablets Market is estimated to be valued at US$ 6.20 Bn in 2025 and is expected to reach US$ 11.41 Bn ...

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

The Business Research Company The Business Research Company's Effective Pain Management Solutions Global Market Report 2025 – Market Size, ...

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- Save 30% On All Global Market Reports With Code ONLINE30 – Stay Informed On Tariff Changes, Macroeconomic Trends, And More.

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...